Navigation Links
Researchers identify novel approach to create red blood cells, platelets in vitro
Date:5/30/2013

(Boston) A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health (BUSPH) and Boston Medical Center (BMC), the researchers differentiated induced pluripotent stem (iPS) cells into these cell types, which are typically obtained through blood donations. This finding could potentially reduce the need for blood donations to treat patients requiring blood transfusions and could help researchers examine novel therapeutic targets to treat a variety of diseases, including sickle cell disease.

Published online in the journal Blood, the study was led by George J. Murphy, PhD, assistant professor of medicine at BUSM and co-director of the Center for Regenerative Medicine (CReM) at Boston University and BMC and performed in collaboration with David Sherr, PhD, a professor in environmental health at BUSM and BUSPH.

iPS cells are derived by reprogramming adult cells into a primitive stem cell state that are capable of differentiating into different types of cells. iPS cells can be generated from mature somatic cells, such as skin or blood cells, allowing for the development of patient-specific cells and tissues that should not elicit inappropriate immune responses, making them a powerful tool for biological research and a resource for regenerative medicine.

In this study, the iPS cells were obtained from the CReM iPS Cell Bank. The cells were exposed to growth factors in order to coax them to differentiate into red blood cells and platelets using a patented technology. These stem cells were examined in depth to study how blood cells form in order to further the understanding of how this process is regulated in the body.

In their new approach, the team added compounds that modulate the aryl hydrocarbon receptor (AhR) pathway. Previous research has shown this pathway to be involved in the promotion of cancer cell development via its interactions with environmental toxins. In this study, however, the team noted an exponential increase in the production of functional red blood cells and platelets in a short period of time, suggesting that AhR plays an important role in normal blood cell development.

"This finding has enabled us to overcome a major hurdle in terms of being able to produce enough of these cells to have a potential therapeutic impact both in the lab and, down the line, in patients," said Murphy. "Additionally, our work suggests that AhR has a very important biological function in how blood cells form in the body."

Blood transfusion is an indispensable cell therapy and the safety and adequacy of the blood supply is an international concern. In 2009, the National Blood Data Resource Center reported that blood-banking institutions collected more than 17 million units of whole blood and red blood cells and US hospitals were transfusing more than 15 million patients annually. Given the variety of blood types, there are even in developed countries chronic shortages of blood for some groups of patients. Sporadic shortages of blood also can occur in association with natural or man-made disasters. The number of blood transfusions is expected to increase in people over the age of 60 and could lead to an insufficient blood supply by 2050.

"Patient-specific red blood cells and platelets derived from iPS cells, which would solve problems related to immunogenicity and contamination, could potentially be used therapeutically and decrease the anticipated shortage and the need for blood donations," added Murphy.

iPS-derived cells have great potential to lead to a variety of novel treatments for diseases given that they can be used to construct disease models in a lab. The iPS-derived red blood cells could be used by researchers examining malaria and sickle cell anemia while the iPS-derived platelets could be used to explore cardiovascular disease and treatments for blood clotting disorders.


'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers shed new light on egg freezing success rates
2. Junk DNA plays active role in cancer progression, researchers find
3. Researchers provide rationale for use of targeted immunotherapy in sarcomatoid lung carcinomas
4. Stanford researchers identify genetic suspects in sporadic Lou Gehrigs disease
5. Researchers identify first drug targets in childhood genetic tumor disorder
6. Researchers find common childhood asthma unconnected to allergens or inflammation
7. Researchers identify networks of neurons in the brain that are disrupted in psychiatric disease
8. Fish Oil Pills Might Cut Diabetes Risk, Researchers Say
9. Researchers find genetic risk factor for pulmonary fibrosis
10. Researchers find genetic tie to improved survival time for pulmonary fibrosis
11. Leading researchers report on the elusive search for biomarkers in Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: